SG11202101888YA - Peptide vaccines - Google Patents

Peptide vaccines

Info

Publication number
SG11202101888YA
SG11202101888YA SG11202101888YA SG11202101888YA SG11202101888YA SG 11202101888Y A SG11202101888Y A SG 11202101888YA SG 11202101888Y A SG11202101888Y A SG 11202101888YA SG 11202101888Y A SG11202101888Y A SG 11202101888YA SG 11202101888Y A SG11202101888Y A SG 11202101888YA
Authority
SG
Singapore
Prior art keywords
peptide vaccines
vaccines
peptide
Prior art date
Application number
SG11202101888YA
Inventor
Julianna Liszewicz
Levente Molnar
Eniko Toke
József Toth
Orsolya Lorincz
Zsolt Csiszovszk
Eszter Somogyi
Katalin Pantya
Mónika Megyesi
Original Assignee
Treos Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1814364.4A external-priority patent/GB201814364D0/en
Priority claimed from GBGB1814367.7A external-priority patent/GB201814367D0/en
Priority claimed from GBGB1814365.1A external-priority patent/GB201814365D0/en
Priority claimed from GBGB1814366.9A external-priority patent/GB201814366D0/en
Application filed by Treos Bio Ltd filed Critical Treos Bio Ltd
Publication of SG11202101888YA publication Critical patent/SG11202101888YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001148—Regulators of development
    • A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001189—PRAME
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/828—Stomach
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
SG11202101888YA 2018-09-04 2019-09-03 Peptide vaccines SG11202101888YA (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1814364.4A GB201814364D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814367.7A GB201814367D0 (en) 2018-09-04 2018-09-04 Peptide Vaccines
GBGB1814365.1A GB201814365D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
GBGB1814366.9A GB201814366D0 (en) 2018-09-04 2018-09-04 Peptide vaccines
PCT/EP2019/073476 WO2020048990A1 (en) 2018-09-04 2019-09-03 Peptide vaccines

Publications (1)

Publication Number Publication Date
SG11202101888YA true SG11202101888YA (en) 2021-03-30

Family

ID=67874441

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202101888YA SG11202101888YA (en) 2018-09-04 2019-09-03 Peptide vaccines

Country Status (16)

Country Link
US (2) US11666644B2 (en)
EP (1) EP3846845A1 (en)
JP (2) JP2021536487A (en)
KR (1) KR20210086612A (en)
CN (1) CN113329761A (en)
AU (1) AU2019334437A1 (en)
BR (1) BR112021004071A2 (en)
CA (1) CA3110760A1 (en)
CL (1) CL2021000532A1 (en)
CO (1) CO2021004019A2 (en)
IL (1) IL281224A (en)
MA (1) MA53543A (en)
MX (1) MX2021002449A (en)
SA (1) SA521421371B1 (en)
SG (1) SG11202101888YA (en)
WO (1) WO2020048990A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201907524UA (en) 2017-03-03 2019-09-27 Treos Bio Zrt Peptide vaccines
EP3846845A1 (en) 2018-09-04 2021-07-14 Treos Bio Limited Peptide vaccines
AU2022270361A1 (en) 2021-05-05 2023-11-16 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US7252829B1 (en) * 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
EP0914142B9 (en) 1996-03-11 2012-01-04 Epimmune Inc. Peptides with increased binding affinity for at least three hla-a3-like molecules
US6617434B1 (en) 1996-05-31 2003-09-09 North Shore Long Island Jewish Research Institute Identificiaton of differentially methylated and mutated nucleic acids
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US20030148463A1 (en) 1997-04-14 2003-08-07 Micromet Ag Novel method for the production of anti-human antigen receptors and uses thereof
US6346389B1 (en) 1998-04-01 2002-02-12 Yale University Method for selectively modulating the interactions between survivin and tubulin
FR2791895B1 (en) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc USE OF TREHALOSE TO STABILIZE A LIQUID VACCINE
EP1235841A4 (en) * 1999-12-10 2006-04-12 Epimmune Inc Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
CA2496888A1 (en) 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
ES2529736T3 (en) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Immunogenic composition comprising a SARS coronavirus spicular protein
US20050100883A1 (en) 2003-11-12 2005-05-12 Wang Chang Y. Peptide-based diagnostic reagents for SARS
PT1691824E (en) 2003-11-19 2009-05-28 Merck Patent Gmbh Proteins belonging to the bcl-2 family and fragments thereof, and their use in cancer patients
CN101434647A (en) 2004-01-20 2009-05-20 爱知县 Epitope/peptide recognized by hla-a2402-restricted ep/cam-specific ctl and use of the same
WO2005118626A2 (en) 2004-06-01 2005-12-15 Innogenetics N.V. Peptides for inducing a ctl and/or htl response to hepatitis c virus
WO2006014579A2 (en) 2004-07-08 2006-02-09 The Regents Of California Enhancing class i antigen presentation with synthetic sequences
JP4475469B2 (en) 2005-01-25 2010-06-09 日本電気株式会社 HLA-binding peptide, DNA fragment encoding it and recombinant vector
JP2008528643A (en) 2005-02-04 2008-07-31 スルバック アーぺーエス Survivin peptide vaccine
CN100402554C (en) 2005-02-25 2008-07-16 李玉新 Preparation and use of testes specificity protein 50 human source antibody
FR2891462B1 (en) * 2005-09-30 2009-10-16 Commissariat Energie Atomique CD4 + EPITOPES OF SURVIVIN AND THEIR APPLICATIONS
GB0520067D0 (en) 2005-10-01 2005-11-09 Cancer Rec Tech Ltd Treatment of cancer
US7993638B2 (en) 2006-03-01 2011-08-09 Janssen Pharmaceutica Nv Cancer treatment combining lymphodepleting agent with CTLs and cytokines
CA2665816C (en) * 2006-09-21 2016-07-12 Vaxil Biotherapeutics Ltd. Antigen specific multi epitope vaccines
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
BRPI0720342A2 (en) 2006-10-04 2018-09-18 Janssen Pharmaceutica N.V. prepared from artificial antigen presenting cells and their use in cell therapies.
US8309096B2 (en) * 2007-01-15 2012-11-13 Glaxosmithkline Biologicals S.A. Fusion protein
EP2361930A3 (en) 2007-03-26 2011-10-26 Dako Denmark A/S Multimers of MHC-peptide complexes and uses thereof in Borrelia infectious diseases
EP2042600A1 (en) 2007-09-28 2009-04-01 Commissariat A L'energie Atomique A public and immunogenic CD4+ T Cell epitope of the hiv tat protein and its applications
SG188907A1 (en) 2008-03-31 2013-04-30 Bioimmulance Co Ltd Partial peptide of survivin presented on mhc class ii molecule and use thereof
NO2119726T3 (en) 2008-05-14 2015-05-23
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
US20120244145A1 (en) 2009-11-16 2012-09-27 Duke University Enhanced immunological responses
US20170039314A1 (en) 2010-03-23 2017-02-09 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2012051282A2 (en) 2010-10-14 2012-04-19 The Ohio State University Research Foundation Piwil2-like (pl2l) proteins-targeted cancer diagnosis and therapy
EP2688904B1 (en) 2011-03-21 2017-12-27 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
EP2956544B1 (en) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
WO2014127276A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd. Ovarian cancer vaccines and vaccination methods
ES2702622T3 (en) 2013-03-27 2019-03-04 Immunovaccine Technologies Inc Method to improve the effectiveness of a survivin vaccine in the treatment of cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
GB201315946D0 (en) 2013-09-06 2013-10-23 Immune Targeting Systems Its Ltd Oncology vaccine
US9884895B2 (en) 2014-03-20 2018-02-06 The University Of North Carolina At Chapel Hill Methods and compositions for chimeric coronavirus spike proteins
WO2015164798A1 (en) 2014-04-25 2015-10-29 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
EP3193892A4 (en) 2014-09-14 2018-09-12 Washington University Personalized cancer vaccines and methods therefor
US20160074489A1 (en) 2014-09-15 2016-03-17 Regen Biopharma, Inc Stimulation of immunity to tumor specific and endothelial specific proteins by in vivo dc attraction and maturation
EP3227679A1 (en) * 2014-12-03 2017-10-11 Verik Bio, Inc. Identification, selection and use of high curative potential t cell epitopes
EP3242883A4 (en) 2015-01-06 2018-10-17 ImmunoVaccine Technologies Inc. Lipid a mimics, methods of preparation, and uses thereof
CA3172682A1 (en) 2015-04-23 2016-10-27 Nantomics, Llc Cancer neoepitopes
GB201507030D0 (en) 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
WO2016176761A1 (en) 2015-05-01 2016-11-10 Immunovaccine Technologies Inc., Methods for potentiating an immune response using depot-forming and non-depot-forming vaccines
US11090332B2 (en) 2015-05-21 2021-08-17 Regen BioPharma, Inc. Antigen specific mRNA cellular cancer vaccines
BR112017027653A2 (en) * 2015-06-29 2018-08-28 Ose Immunotherapeutics method for inducing early t memory response with short peptide anti-tumor vaccine
MA42895A (en) 2015-07-15 2018-05-23 Juno Therapeutics Inc MODIFIED CELLS FOR ADOPTIVE CELL THERAPY
US9790562B2 (en) 2015-09-30 2017-10-17 Augusta University Research Institute, Inc. Compositions and methods for the detection or treatment of uterine leiomyosarcoma
JP2018532736A (en) 2015-10-12 2018-11-08 ナントミクス，エルエルシー Systems, compositions, and methods for MSI and neoepitope search to predict susceptibility to checkpoint inhibitors
CN105219723A (en) * 2015-10-20 2016-01-06 上海隆耀生物科技有限公司 A kind of test kit for activating cancer of the stomach specific immune response
CN108430505A (en) 2015-11-18 2018-08-21 免疫疫苗技术有限公司 The auxiliary system of adjuvant including polyinosinic acid polynucleotides adjuvant and based on lipid and anhydrous vaccine composition
GB201604755D0 (en) 2016-03-21 2016-05-04 Vaxeal Res Sas Immunogenic compositions
JP7329439B2 (en) 2016-05-13 2023-08-18 エムビーエル インターナショナル コーポレイション Peptide exchange system and method
IL265834B2 (en) 2016-10-07 2023-03-01 Univ Texas Hla-restricted vgll1 peptides and use thereof
WO2018102585A1 (en) 2016-11-30 2018-06-07 Advaxis, Inc. Personalized immunotherapy in combination with immunotherapy targeting recurrent cancer mutations
WO2018138257A1 (en) 2017-01-27 2018-08-02 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3369431A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Vaccine
EP3370065A1 (en) 2017-03-03 2018-09-05 Treos Bio Kft Immunogenic peptides
SG11201907524UA (en) 2017-03-03 2019-09-27 Treos Bio Zrt Peptide vaccines
EP3651733A4 (en) 2017-07-10 2021-04-07 ImmunoVaccine Technologies Inc. Pharmaceutical compositions, methods for preparation using lipid vesicle particles of defined size, and uses thereof
EP3707152A4 (en) 2017-11-08 2021-12-01 Advaxis, Inc. Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof
AU2017438994A1 (en) 2017-11-09 2020-05-28 Immunovaccine Technologies Inc. Pharmaceutical compositions, methods for preparation comprising sizing of lipid vesicle particles, and uses thereof
CA3086923A1 (en) 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
EP3796923A4 (en) 2018-05-18 2022-03-09 Children's National Medical Center Improved targeted t-cell therapy
WO2019222762A1 (en) 2018-05-18 2019-11-21 Children's National Medical Center Improved cell therapy compositions for hematopoietic stem cell transplant patients
EP3846845A1 (en) 2018-09-04 2021-07-14 Treos Bio Limited Peptide vaccines
GB201814362D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Composition and process for preparing vaccine
GB201814361D0 (en) 2018-09-04 2018-10-17 Treos Bio Zrt Immunogenetic cancer screening test
US20220125903A1 (en) 2018-11-19 2022-04-28 Immunovaccine Technologies Inc. Methods for improving the efficacy of a survivin therapeutic in the treatment of tumors
EP3908293A4 (en) 2019-01-07 2023-01-11 Children's National Medical Center Ex vivo activated t-lymphocytic compositions and methods of using the same
US20220062342A1 (en) 2019-01-07 2022-03-03 Children's National Medical Center Improved targeted t-cell therapy for treatment of multiple myeloma
US20230000769A1 (en) 2019-10-16 2023-01-05 Immunovaccine Technologies Inc. Oil-in-water emulsion formulations for delivery of active or therapeutic agents
CN110713546B (en) 2019-10-31 2021-04-20 中国医科大学附属第一医院 survivin-XIAP compound-targeted antitumor polypeptide Sur-X and application thereof
GB202004974D0 (en) 2020-04-03 2020-05-20 Treos Bio Ltd Coronavirus vaccine

Also Published As

Publication number Publication date
US11666644B2 (en) 2023-06-06
JP2021536487A (en) 2021-12-27
JP2024097033A (en) 2024-07-17
CA3110760A1 (en) 2020-03-12
US20240000911A1 (en) 2024-01-04
SA521421371B1 (en) 2024-06-06
IL281224A (en) 2021-04-29
MX2021002449A (en) 2021-08-05
MA53543A (en) 2021-07-14
EP3846845A1 (en) 2021-07-14
CO2021004019A2 (en) 2021-07-19
CL2021000532A1 (en) 2021-09-24
KR20210086612A (en) 2021-07-08
US20230102031A1 (en) 2023-03-30
CN113329761A (en) 2021-08-31
AU2019334437A1 (en) 2021-03-18
WO2020048990A1 (en) 2020-03-12
BR112021004071A2 (en) 2021-06-01

Similar Documents

Publication Publication Date Title
IL268920A (en) Peptide vaccines
IL275298A (en) Mitochondria-targeting peptides
IL281224A (en) Peptide vaccines
IL288412A (en) Peptides
SG11202005653RA (en) Novel peptide
GB201910794D0 (en) Vaccine
GB201700557D0 (en) Novel peptides
IL278830A (en) Reverse peptide vaccine
IL284006A (en) Mitochondria-targeting peptides
GB201811382D0 (en) Vaccine
GB201810052D0 (en) Polypeptide
GB201719520D0 (en) Neuroprotectvie peptide
GB201814367D0 (en) Peptide Vaccines
GB201814366D0 (en) Peptide vaccines
GB201814365D0 (en) Peptide vaccines
GB201814364D0 (en) Peptide vaccines
GB201814440D0 (en) Peptide
GB201807863D0 (en) Peptides
GB201806181D0 (en) Peptides
GB201805807D0 (en) Peptides
GB201805809D0 (en) Peptides
GB201805801D0 (en) Peptides
GB201807303D0 (en) Glyconjugate vaccines
GB201803074D0 (en) Peptide
IL290019A (en) Melanocyte-regulating peptides